Everything below concerns subcutaneous dosing. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-13. Numbers and descriptions here follow the published literature rather than marketing material.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 39-residue peptide | GIP-derived backbone with non-natural residues |
| Molar mass | Approximately 4.8 kDa | Peptide chain plus linker and lipid modifications |
| Appearance | White to off-white powder | Typical of lyophilized research material |
| Solubility | Soluble in water and aqueous buffer | Practically insoluble in nonpolar solvents |
| Storage temperature | Typically −20 °C for dry powder | Solutions usually held at 2–8 °C short term |
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
During this period, the Assad government arrested numerous journalists and shut down independent press centres, in addition to tightening its censorship of the Internet. From 2011 to 2015, the last four years of the Syrian war, the freedom of movement has been most widely restricted in certain areas and on certain individuals. Restrictions vary between regions, partly because of continuous fighting in certain areas. In rebel held areas there are severe restrictions on the movement of government supporters (or people thought to be government supporters). Foreign diplomats are unable to visit a majority of Syria, and are often not allowed outside of Damascus (Syrian capital). In the areas of Jindires in Afrin, and Ras al Ayn, curfews were executed in 2012 and 2013 as rebel groups put in place a curfew of 5 pm, after which nobody could be seen in public. Then in December 2014, a travel ban was announced on Syrian men aged 18 to 42 (military age). The memorandum supposedly states that all Syrian males must have special permission to leave the country, obtained from army officials. An example of an individual travel ban is Louay Hussein, president of an opposition group in Syria (Building the Syrian State, or the BSS party), was unable to attend peace talks in Moscow in April 2015 because the government refused to rid of his lifelong travel ban, however on 26 April 2015 Hussein managed to evade his ban and flee to Spain. Also Syrian human rights defenders are having their movement restrained by being held in arbitrary arrest.
Pilonidal cysts can recur, and do so more frequently if the surgical wound is sutured in the midline, as opposed to away from the midline, which obliterates the natal cleft and removes the focus of shearing stress. An incision lateral to the intergluteal cleft is therefore preferred, especially given the poor healing of midline incisions in this region. Minimally invasive techniques with no wound and rapid return to full activities have been reported but await double-blind randomized trials. Another technique is to treat the pilonidal sinus with fibrin glue. This technique is of unclear benefit as of 2017 due to insufficient research. The evidence for any treatment is of low quality, and care must be taken not to overinterpret any study in this field. Since the 2010s, several minimally invasive techniques have been developed to minimize the impact of surgery on patients and achieve less pain and shorter recovery times. In some cases, the wounds are left open after surgery to heal naturally instead of being closed with stitches. There are a lot of different dressings and topical agents (creams or lotions) that are available to help these open wounds heal. A 2022 systematic review brought together evidence from 11 studies that compared dressings and topical agents for treating open wounds after surgical treatment for pilonidal sinus of the buttocks.
Natural food freezing (using winter frosts) had been in use by people in cold climates for centuries. In 1861 Thomas Sutcliffe Mort established at Darling Harbour in Sydney, Australia, the world's first freezing works, which later became the New South Wales Fresh Food and Ice Company. Mort financed experiments by Eugene Dominic Nicolle, a French born engineer who had arrived in Sydney in 1853 and registered his first ice-making patent in 1861. The first trial shipment of frozen meat to London was in 1868. Although their machinery was never used in the frozen meat trade, Mort and Nicolle developed commercially viable systems for domestic trade. The financial return on that investment was minimal for Mort. Regular shipments of frozen meat from Australia and New Zealand to Europe began in 1881, with a consignment of frozen New Zealand sheep exported to London on board the Dunedin. By 1885 a small number of chickens and geese were being shipped from Russia to London in insulated cases using this technique. By March 1899, the "British Refrigeration and Allied Interests" reported that a food importing business, "Baerselman Bros", was shipping some 200,000 frozen geese and chickens per week from three Russian depots to New Star Wharf, Lower Shadwell, London over three or four winter months. This trade in frozen food was enabled by the introduction of Linde cold air freezing plants in three Russian depots and the London warehouse. The Shadwell warehouse stored the frozen goods until they were shipped to markets in London, Birmingham, Liverpool and Manchester.
Sources: en.wikipedia.org
substrate 1. A chemical compound or molecule upon which a particular enzyme directly acts, often but not necessarily binding the molecule by forming one or more chemical bonds. See also ligand. 2. The substance, biotic or abiotic, upon which an organism grows or lives, or by which it is supported; e.g. a particular growth medium used in cell culture. See also substratum.
Zverev started his 2022 season by representing Germany at the ATP Cup. Germany was in Group C alongside Great Britain, the US, and Canada. Against Great Britain, he beat Cameron Norrie. Great Britain ended up winning the tie over Germany 2–1. Against the US, he defeated Taylor Fritz. Germany won the tie 2–1 over the USA. Against Canada, he lost to Félix Auger-Aliassime in three sets. Canada won the tie over Germany 2–1. Germany not only failed to qualify for the semi-finals, but they also ended third in Group C. Seeded third at the Australian Open, he reached the fourth round where he was defeated by 14th seed, Denis Shapovalov, in straight sets. After the Australian Open, Zverev played at the Open Sud de France. As the top seed, he made it to the final where he lost to sixth seed Alexander Bublik. Seeded second at the Mexican Open, Zverev played in what was the record latest match ever played, defeating Jenson Brooksby at 4:55 A.M. He was then defaulted from the tournament ahead of his following match against compatriot, Peter Gojowczyk, for violently and repeatedly hitting the umpire's chair with his racket after his loss in doubles. Representing Germany in the Davis Cup tie against Brazil, he won both of his matches by beating Thiago Seyboth Wild and Thiago Monteiro. Germany ended up winning the tie over Brazil 3–1 to qualify for the Davis Cup Finals. Seeded third at the Indian Wells Masters, he was stunned in his second-round match by Tommy Paul.
Single shot semi-automatic, in which the gunner can shoot as fast as the trigger can be operated, limited only by the electrical drive speed (it cannot exceed the "high rate" firing speed). Low rate fully automatic, in which the weapon fires 100 rounds per minute, ± 25 rounds. High rate fully automatic, in which the weapon fires 200 rounds per minute, ± 25 rounds.
The venous system is the system of veins in the systemic and pulmonary circulations that return blood to the heart. In the systemic circulation the return is of deoxygenated blood from the organs and tissues of the body, and in the pulmonary circulation the pulmonary veins return oxygenated blood from the lungs to the heart. Almost 70% of the blood in the body is in the veins, and almost 75% of this blood is in the small veins and venules. All of the systemic veins are tributaries of the largest veins, the superior and inferior vena cava, which empty the oxygen-depleted blood into the right atrium of the heart. The thin walls of the veins, and their greater internal diameters (lumens) enable them to hold a greater volume of blood, and this greater capacitance gives them the term of capacitance vessels. This characteristic also allows for the accommodation of pressure changes in the system. The whole of the venous system, bar the post-capillary venules is a large volume, low pressure system. The venous system is often asymmetric, and whilst the main veins hold a relatively constant position, unlike arteries, the precise location of veins varies among individuals.
Sources: en.wikipedia.org
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.
It is given by subcutaneous injection, generally on a weekly schedule. Dosing usually begins low and increases in steps to limit gastrointestinal side effects. Formulated product is supplied as a ready-to-use pen or vial in most markets.
No. Receptor engagement is documented, but how central appetite circuits, gut signals, and insulinotropic effects combine is incompletely resolved. Investigators continue to separate GIP-driven from GLP-1-driven contributions in animal and human models.
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.